Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, CHIEF LEGAL OFFICER | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,929 |
Ending reported balance
After 2026-06-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-12 · Exercise / conversion · Acquired 5,034 · Balance 52,644 Row 2 · 2026-06-12 · Tax withholding · Disposed 2,715 · Balance 49,929 F1: The reported disposition of 2,715 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 10,068 |
Reported balance
After 2026-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-12 · Exercise / conversion · Disposed 5,034 · Balance 10,068 F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported disposition of 2,715 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2024 Filed Jan 5, 2024 21:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 7,611 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-000768 · form4-01052024_090119.xml · derivative · entry 3 Snyder Mark Howard · CIK 0001902866 · SVP, GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,222 Underlying: Common Stock · 7,611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,957 | $35.78 | $105,801.46 |
DisclosureSEC source: 0001415889-24-000768 · form4-01052024_090119.xml · nonDerivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,461 F1 · shares: The reported disposition of 2,957 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 7,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-000768 · form4-01052024_090119.xml · nonDerivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 00:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 19,184 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002955 · form4-02222023_120223.xml · derivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,184 Underlying: Common Stock · 19,184 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 00:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 54,955 | $0.00 Strike: $49.26 | $0.00 |
DisclosureSEC source: 0001415889-23-002955 · form4-02222023_120223.xml · derivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,955 Underlying: Common Stock · 54,955 shares Expires 2033-02-16 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:00 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 7,611 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000393 · form4-01042023_110131.xml · derivative · entry 3 Snyder Mark Howard · CIK 0001902866 · SVP, GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,833 Underlying: Common Stock · 7,611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:00 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,804 | $55.13 | $154,584.52 |
DisclosureSEC source: 0001415889-23-000393 · form4-01042023_110131.xml · nonDerivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,807 F1 · shares: The reported disposition of 2,804 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:00 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 7,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000393 · form4-01042023_110131.xml · nonDerivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:13 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Unit · Derivative | 30,444 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000243 · edgar.xml · derivative · entry 2 Snyder Mark Howard · CIK 0001902866 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,444 Underlying: Common Stock · 30,444 shares Expires 2032-01-03 F2 · derivative.exercise_date: This restricted stock unit grant vests one-fourth on such date and then one-fourth on each anniversary thereafter. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:13 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 83,142 | $0.00 Strike: $41.06 | $0.00 |
DisclosureSEC source: 0001179110-22-000243 · edgar.xml · derivative · entry 1 Snyder Mark Howard · CIK 0001902866 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,142 Underlying: Common Stock · 83,142 shares Expires 2032-01-03 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.